Bepotastine besilate

Drug Profile

Bepotastine besilate

Alternative Names: Bepotastine; Bepreve; Betotastine; Betotastine besilate; Talion; Talion OD Tablets; TAU-284

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ube Industries
  • Developer ISTA Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Ube Industries
  • Class Antiallergics; Antiasthmatics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Pruritus; Urticaria
  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 14 Aug 2015 No recent reports on development identified - Phase-II for Seasonal allergic rhinitis in USA (Intranasal)
  • 26 May 2015 Registered for Perennial allergic rhinitis (In adolescents, In children) in Japan (PO)
  • 01 Nov 2013 Mitsubishi Tanabe Pharma completes a phase III trial in Perennial allergic rhinitis (in paediatric patients) in Japan (NCT01900054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top